ID   501-mel
AC   CVCL_4633
AS   CVCL_C608
SY   501-MEL; 501 mel; 501 Mel; 501Mel; 501mel; 501MEL; 501; Mel 501; Mel501; MEL501; Me 501; Me-501; Me501
DR   BTO; BTO:0002956
DR   cancercelllines; CVCL_4633
DR   CGH-DB; 9296-4
DR   Cosmic; 686481
DR   Cosmic; 876680
DR   Cosmic; 905210
DR   Cosmic; 1197392
DR   Cosmic; 1238106
DR   Cosmic; 1458962
DR   Cosmic; 1559440
DR   Cosmic; 2159451
DR   Cosmic; 2163827
DR   Cosmic; 2440478
DR   ESTDAB; ESTDAB-120
DR   GEO; GSM188239
DR   GEO; GSM188269
DR   GEO; GSM188328
DR   GEO; GSM433918
DR   GEO; GSM555120
DR   GEO; GSM555174
DR   IGRhCellID; 501Mel
DR   Progenetix; CVCL_4633
DR   Wikidata; Q54603677
RX   PubMed=8027550;
RX   PubMed=9670966;
RX   PubMed=10048982;
RX   PubMed=15467732;
RX   PubMed=15592718;
RX   PubMed=20149136;
RX   PubMed=21343389;
RX   PubMed=23671654;
RX   PubMed=23851445;
RX   PubMed=25950383;
RX   PubMed=25960936;
RX   PubMed=30674989;
CC   From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPB1*04:01,02:01:02; DQB1*06:03,05:01; DRB1*11:01:01,04:01:01 (PubMed=15592718).
CC   HLA typing: A*02:01,24:02; B*18:01,35:08; C*04:04,07:01 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
CC   Omics: Exosome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ESTDAB
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   FGA: 22,23
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1DM ! 501-EBV
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=20149136; DOI=10.1111/j.1755-148X.2010.00685.x;
RA   Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S.,
RA   Krauthammer M., McCusker J.P., Kluger Y., Sznol M.;
RT   "PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK
RT   pathway and enhances cell migration and proliferation of BRAF melanoma
RT   cells.";
RL   Pigment Cell Melanoma Res. 23:190-200(2010).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25950383; DOI=10.1111/pcmr.12380;
RA   Lazar I., Clement E., Ducoux-Petit M., Denat L., Soldan V.,
RA   Dauvillier S., Balor S., Burlet-Schiltz O., Larue L., Muller C.,
RA   Nieto L.;
RT   "Proteome characterization of melanoma exosomes reveals a specific
RT   signature for metastatic cell lines.";
RL   Pigment Cell Melanoma Res. 28:464-475(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=30674989; DOI=10.1038/s41388-018-0640-2;
RA   Mancuso P., Tricarico R., Bhattacharjee V., Cosentino L., Kadariya Y.,
RA   Jelinek J., Nicolas E., Einarson M., Beeharry N., Devarajan K.,
RA   Katz R.A., Dorjsuren D.G., Sun H.-M., Simeonov A., Giordano A.,
RA   Testa J.R., Davidson G., Davidson I., Larue L., Sobol R.W., Yen T.J.,
RA   Bellacosa A.;
RT   "Thymine DNA glycosylase as a novel target for melanoma.";
RL   Oncogene 38:3710-3728(2019).
//